We previously reported that the application of DBS treatment (which is primarily aimed at treating motor response complications, and to some extent also tremor) did not seem to be over-represented among carriers of LRRK2 risk variant carriers, in contrast to GBA1 mutation carriers69. The gene discussed is GBA1; the disease is Tremor.